NCT07146919 2025-08-28
ANGELICA
Centre Leon Berard
Phase 1/2 Not yet recruiting
Clinical Trials
14 trialsNCT06023862 2025-06-15
DOVE
Yonsei University
Phase 2 Recruiting
NCT03556839 2025-01-08
BEATcc
Grupo Español de Investigación en Cáncer de Ovario
Phase 3 Active not recruiting
NCT03367871 2024-06-18
Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer
University of Miami
Phase 2 Terminated
NCT03476798 2024-02-15
Clovis-001
University of Oklahoma
Phase 2 Completed
NCT05247619 2022-07-15
A Clinical Study to Explore the Efficacy and Safety of Tislelizumab in Combination With Bevacizumab and Chemotherapy in Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
Zhejiang Cancer Hospital
Phase 2 Unknown
NCT05444374 2022-07-05
A Phase II Study of Serplulimab Plus Bevacizumab in Combination With Chemotherapy in 1L Treatment of Untreated Recurrent or Metastatic Cervical Cancer
Sichuan Cancer Hospital and Research Institute
Phase 2 Unknown
NCT04974944 2021-10-01
First-line Treatment With Camrelizumab + Apatinib Versus Chemotherapy + Bevacizumab in Advanced Cervical Cancer
Sun Yat-sen University
Phase 2 Unknown
NCT04973904 2021-07-22
Toripalimab Combined With Chemotherapy and Bevacizumab as First-Line Treatment in Patients With Advanced Cervical Cancer
Peking Union Medical College Hospital
Phase 2 Unknown
NCT02835833 2018-07-10
Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors
University of Alabama at Birmingham
Phase 1 Completed
NCT00600210 2017-08-23
Neoadjuvant Bevacizumab and Carboplatin Followed by Concurrent Bevacizumab, Carboplatin and Radiotherapy in the Primary Treatment of Cervix Cancer
Leo W. Jenkins Cancer Center
Phase 2 Withdrawn
NCT00545792 2017-03-15
Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00548418 2014-08-01
Topotecan, Cisplatin and Bevacizumab for Recurrent/Persistent Cervical Cancer
Washington University School of Medicine
Phase 2 Completed
NCT00626561 2014-07-07
Bevacizumab and Paclitaxel for Neuroendocrine Tumors of the Cervix
M.D. Anderson Cancer Center
Phase 2 Terminated